HEPION PHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.349 USD | +8.81% |
|
+7.08% | -58.36% |
| Apr. 22 | Sector Update: Health Care Stocks Increase Late Afternoon | MT |
| Apr. 22 | Sector Update: Health Care | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 18.51 | 70.14 | 86.9 | 22.89 | 14.05 | 6.786 | - | - |
| Enterprise Value (EV) 1 | 18.51 | 29.58 | 86.9 | 22.89 | 14.05 | 6.786 | 6.786 | 6.786 |
| P/E ratio | -0.9 x | -1.04 x | -2.43 x | -0.51 x | - | -0.11 x | - | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | -3,487,299 x | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 173 | 1,601 | 3,811 | 3,811 | 4,338 | 5,472 | - | - |
| Reference price 2 | 107.2 | 43.80 | 22.80 | 6.006 | 3.240 | 1.240 | 1.240 | 1.240 |
| Announcement Date | 5/14/20 | 3/31/21 | 4/8/22 | 4/10/23 | 4/16/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | -20.11 | - | - | - | - | - | - |
| EBIT 1 | -7.77 | -20.15 | -30.4 | -43.62 | - | -51.55 | -76.09 | -90.5 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.946 | -20.32 | -32.72 | -45.08 | -49.34 | -51.55 | -76.09 | -90.5 |
| Net income 1 | -6.719 | -20.36 | -32.72 | -45.34 | -48.93 | -51.55 | -76.09 | -90.5 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -119.0 | -42.00 | -9.400 | -11.80 | - | -11.43 | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 5/14/20 | 3/31/21 | 4/8/22 | 4/10/23 | 4/16/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | -9 | -7.252 | -20 | -8.465 | -7.902 | -13.21 | -14.17 | -10.66 | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -9.733 | -6.93 | -19.91 | -8.548 | -9.695 | -13.26 | -14.08 | -10.53 | -11.47 |
| Net income 1 | -9.267 | -9.733 | -6.93 | -19.91 | -8.548 | -9.949 | -13.26 | -14.08 | -10.53 | -11.06 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS | -2.400 | -2.600 | -1.800 | -5.200 | -2.200 | -2.600 | -3.480 | -3.680 | -2.740 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 4/8/22 | 5/16/22 | 8/15/22 | 11/14/22 | 4/10/23 | 5/12/23 | 8/14/23 | 11/20/23 | 4/16/24 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | 40.6 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 5/14/20 | 3/31/21 | 4/8/22 | 4/10/23 | 4/16/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.24
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.36% | 6.79M | |
| +9.53% | 114B | |
| +11.56% | 104B | |
| -13.84% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.76% | 17.89B | |
| +7.39% | 14.28B | |
| +35.84% | 12.55B |
- Stock Market
- Equities
- HEPA Stock
- Financials Hepion Pharmaceuticals, Inc.
